ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Boehringer Tries Drug Crowdsourcing …

by Rick Mullin
September 28, 2015 | APPEARED IN VOLUME 93, ISSUE 38

Boehringer Ingelheim and BioMed X say they used crowdsourcing to establish a team of scientists to identify new approaches for the treatment of chronic obstructive pulmonary disease (COPD). The team will try to characterize the epigenetic regulators underlying COPD. The team will assemble at BioMed X’s center in Heidelberg, Germany, which sponsors early-career scientists to work on preclinical research projects.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment